Current options for treating hyperuricemia include inhibitors of uric acid production, such as the XOIs febuxostat and allopurinol, and older uricosurics promoting uric acid excretion (including via URAT1 inhibition) such as benzbromarone, probenecid, sulfinpyrazone, and the selective URAT1 inhibitor lesinurad. This evidence concerns the gene SLC22A12 and hyperuricemia.